Diabetes and Metabolic Disorders: Their Impact on Cardiovascular Events in Liver Transplant Patients

Overview

Journal Can J Gastroenterol Hepatol

Specialty Gastroenterology

Date 2023 Jul 3

PMID 37396501

Authors

Simone Di Cola

Giulia Cusi

Lucia Lapenna

Jakub Gazda

Stefano Fonte

Marco Mattana

Gianluca Mennini

Patrizio Pasqualetti

Manuela Merli

Affiliations

Soon will be listed here.

Abstract

Cardiovascular diseases are currently one of the most important causes of morbidity and mortality in liver transplant patients over the long term. Therefore, evaluating prognostic factors for cardiovascular events (CVEs) in this population is essential for taking preventive measures. The aim of this study was to identify the impact of diabetes and other metabolic disorders on CVEs in liver transplant patients. Three hundred fifty-six liver transplant recipients who survived at least 6 months after surgery were enrolled. Patients were followed for a median time of 118 months (12-250 months). All cardiovascular events were carefully recorded and detailed in the patients' charts. Demographic data, diabetes, hypertension, dyslipidemia, weight changes, and a diagnosis of metabolic syndrome both before and after transplantation were noted to assess their possible relationship with CVE. The presence of a diagnosis of metabolic-associated fatty liver disease (MAFLD) was also evaluated. Immunosuppressive therapy was included in the analysis. Diabetes mellitus (DM), especially when present before transplantation, was strongly associated with CVEs (hazard risk HR 3.10; 95% confidence interval CI: 1.60-6.03). Metabolic syndrome was found to be associated with CVEs in univariate analysis (HR 3.24; 95% CI: 1.36-7.8), while pretransplantation and de novo MAFLD were not. Immunosuppressive therapy had no influence on predisposing transplanted patients to CVEs during follow-up. Further prospective studies may be useful in investigating the risk factors for CVEs after liver transplantation and improving the long-term survival of transplant patients.

Citing Articles

Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) after Liver Transplantation: A Narrative Review of an Emerging Issue.

Savino A, Loglio A, Neri F, Camagni S, Pasulo L, Luca M J Clin Med. 2024; 13(13).

PMID: 38999436 PMC: 11242808. DOI: 10.3390/jcm13133871.

Complications in Post-Liver Transplant Patients.

Agostini C, Buccianti S, Risaliti M, Fortuna L, Tirloni L, Tucci R J Clin Med. 2023; 12(19).

PMID: 37834818 PMC: 10573382. DOI: 10.3390/jcm12196173.

References

Lattanzi B, DAmbrosio D, Tavano D, Pitoni D, Mennini G, Ginanni Corradini S . Weight Gain and Metabolic Disorders after Liver Transplantation. Nutrients. 2019; 11(12). PMC: 6950162. DOI: 10.3390/nu11123015. View

Hecking M, Sharif A, Eller K, Jenssen T . Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics. Transpl Int. 2020; 34(1):27-48. PMC: 7839745. DOI: 10.1111/tri.13783. View

Ferreira S, Penaforte F, Cardoso A, da Silva M, Lima A, Correia M . Association of food cravings with weight gain, overweight, and obesity in patients after liver transplantation. Nutrition. 2019; 69:110573. DOI: 10.1016/j.nut.2019.110573. View

De Luca L, Kalafateli M, Bianchi S, Alasaker N, Buzzetti E, Rodriguez-Peralvarez M . Cardiovascular morbidity and mortality is increased post-liver transplantation even in recipients with no pre-existing risk factors. Liver Int. 2019; 39(8):1557-1565. DOI: 10.1111/liv.14185. View

Li B, Zhang C, Zhan Y . Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. Can J Gastroenterol Hepatol. 2018; 2018:2784537. PMC: 6051295. DOI: 10.1155/2018/2784537. View

Battistella S, DArcangelo F, Grasso M, Zanetto A, Gambato M, Germani G . Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management. Clin Mol Hepatol. 2022; 29(Suppl):S286-S301. PMC: 10029965. DOI: 10.3350/cmh.2022.0392. View

Laryea M, Watt K, Molinari M, Walsh M, McAlister V, Marotta P . Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl. 2007; 13(8):1109-14. DOI: 10.1002/lt.21126. View

Kim N, Sharma A, Saab S . Cardiovascular and metabolic disease in the liver transplant recipient. Best Pract Res Clin Gastroenterol. 2020; 46-47:101683. DOI: 10.1016/j.bpg.2020.101683. View

Kim D, Konyn P, Sandhu K, Dennis B, Cheung A, Ahmed A . Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021; 75(6):1284-1291. DOI: 10.1016/j.jhep.2021.07.035. View

10.

Eslam M, Newsome P, Sarin S, Anstee Q, Targher G, Romero-Gomez M . A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73(1):202-209. DOI: 10.1016/j.jhep.2020.03.039. View

11.

Desai S, Hong J, Saab S . Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management. Liver Int. 2010; 30(7):948-57. DOI: 10.1111/j.1478-3231.2010.02274.x. View

12.

Lee H, Lee Y, Kim S, Kim H . Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2020; 19(10):2138-2147.e10. DOI: 10.1016/j.cgh.2020.12.022. View

13.

Henchoz S, Fraga M, Saouli A, Elkrief L, Berney T, Toso C . [Outpatient follow-up of liver transplant recipients: the essential role of the general practitioner]. Rev Med Suisse. 2019; 15(660):1488-1495. View

14.

Apovian C . Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016; 22(7 Suppl):s176-85. View

15.

Roccaro G, Goldberg D, Hwang W, Judy R, Thomasson A, Kimmel S . Sustained Posttransplantation Diabetes Is Associated With Long-Term Major Cardiovascular Events Following Liver Transplantation. Am J Transplant. 2017; 18(1):207-215. PMC: 5740009. DOI: 10.1111/ajt.14401. View

16.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M . 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of.... J Hypertens. 2018; 36(10):1953-2041. DOI: 10.1097/HJH.0000000000001940. View

17.

Yang L, Shan L, Saxena A, Morris D . Liver transplantation: a systematic review of long-term quality of life. Liver Int. 2014; 34(9):1298-313. DOI: 10.1111/liv.12553. View

18.

Anastacio L, Diniz K, Ribeiro H, Ferreira L, Lima A, Correia M . Prospective evaluation of metabolic syndrome and its components among long-term liver recipients. Liver Int. 2014; 34(7):1094-101. DOI: 10.1111/liv.12495. View

19.

Alarcon R, Tiberghien M, Trouillet R, Pelletier S, Luquiens A, Ahmed S . Sugar intake and craving during alcohol withdrawal in alcohol use disorder inpatients. Addict Biol. 2020; 26(2):e12907. DOI: 10.1111/adb.12907. View

20.

Albeldawi M, Aggarwal A, Madhwal S, Cywinski J, Lopez R, Eghtesad B . Cumulative risk of cardiovascular events after orthotopic liver transplantation. Liver Transpl. 2011; 18(3):370-5. DOI: 10.1002/lt.22468. View